The potential role of PGC-1α-induced mitochondrial biogenesis as a therapeutic target for sarcopenia is suggested by several preclinical studies, which used agents such as ghrelin, trimetazidine, exerkine, and 5,7-dimethoxyflavone to reverse sarcopenia [125,126,127,128]. This evidence concerns the gene GHRL and sarcopenia.